Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board.
Paula brings deep expertise in psychopharmacology, using animal and human translational models to understand the biology of schizophrenia and Alzheimer’s disease. Following on from her PhD at the University of Ireland, Paula spent 6 years as a Scientist in the Pharmaceutical Industry, working on a number of drug discovery projects for various CNS disorders. Moving back into academia thorough an EU research fellowship, Paula joined the Institute of Psychiatry at King’s College London to focus on her schizophrenia research before holding senior posts at Universities of Leicester and Nottingham, as Associate Professor and Reader in Behavioural Neuroscience. Paula has been external affairs officer for the British Association of Pharmacology and a member of the scientific advisory panel for the European College of Neuropsychopharmacology for psychosis and its associated disorders.
For further information, contact:
Jenny Barnett, CEO
Richard Hayhurst/Janet Joy
E: Richard@rhapr.eu or email@example.com
Tel: +44 7711 821527
Notes to Editors:
About Monument Therapeutics
Monument Therapeutics is bringing stratified medicine to neuroscience drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.
For further information visit www.monumenttx.com